Sometimes diet and exercise are not enough to help the 100 million Americans with obesity lose weight and prevent health ...

Terns Pharma is in the process of developing TERN-601 for the treatment of patients with obesity. See why I rate TERN stock ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...

Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight loss than its blockbuster weekly injection, Wegovy (semaglutide), in a phase I study. Not only did NVO’s stock rise 4% in ...

An experimental obesity pill being developed by Ozempic-maker Novo Nordisk showed only limited additional weight loss when taken in higher doses compared to the lowest dose tested in a mid-stage ...